Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st.
Dr Parsey will be responsible for and oversee the company’s global clinical development and medical affairs organisations – reporting directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer.
Parsey joins Gilead from Genentech, a member of the Roche group, where he currently holds the position of Senior Vice President of Early Clinical Development. In this particular role he has lead clinical development, quality, compliance, informatics and clinical operations functions.
Daniel O’Day, on the hiring of Parsey, said: “I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead.
“Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”
Prior to his most recent position at Genentech, Dr. Prasey has worked as President and CEO of 3-V Biosciences and has also held development roles at Sepracor, Regeron and MSD.
Parsey commented: “I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired.
“I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”